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a b s t r a c t
Chikungunya virus (CHIKV) causes an acute clinical illness characterized by sudden high fever, intense
joint pain, and skin rash. Recent outbreaks of chikungunya disease in Africa and Asia are a major public
health concern; however, there is currently no effective licensed vaccine or speciﬁc treatment. This study
reported the development of a mouse monoclonal antibody (MAb), CK47, which recognizes domain III
within the viral envelope 1 protein and inhibited the viral release process, thereby preventing the
production of progeny virus. The MAb had no effect on virus entry and replication processes. Thus, CK47
may be a useful tool for studying the mechanisms underlying CHIKV release and may show potential as a
therapeutic agent.
& 2014 Elsevier Inc. All rights reserved.
Introduction
Chikungunya virus (CHIKV) is the causative agent of an
arthropod-borne viral disease transmitted by Aedes spp. mosqui-
toes. CHIKV was ﬁrst isolated from a febrile patient during a
chikungunya outbreak in Tanzania in 1953 (Robinson, 1955), and
since then has spread to numerous countries in East, Central, and
South Africa (ECSA) as well as Southeast Asia. Since 2000,
chikungunya disease has become a serious public health problem
and the symptoms have tended to become more severe (Charrel
et al., 2007). The rapid spread across continents means that the
disease is fast becoming a global public health concern (Pialoux
et al., 2007; Burt et al., 2012). Infection with CHIKV causes an acute
illness characterized by sudden high fever (438.9 1C), skin rash,
and severe joint pain. Most patients recover within 2 weeks;
however, some suffer a progressive form of the disease that causes
incapacitating arthritis that can persist for months or even years
(Simon et al., 2011). There is no licensed vaccine or effective
therapeutic agent for use in humans (Weaver et al., 2012).
CHIKV is an enveloped alphavirus belonging to the family
Togaviridae. The viral genome comprises a single-stranded positive-
sense RNA that encodes four nonstructural proteins (nsP1, nsP2,
nsP3, and nsP4), and ﬁve structural proteins, including a capsid
(C) protein, three envelope (E) glycoproteins (E1, E2, and E3), and a
small molecule, 6 K (Jose et al., 2009; Strauss and Strauss, 1994).
Mature alphavirus particles express E1 and E2 heterodimers, which
form 80 trimeric spikes on the surface of the virion (Lee et al., 2011;
Kielian, 2010). The ectodomain E1 protein comprises three domains:
domain I (DI), DII (containing the hydrophobic fusion loop at amino
acid position 83–89), and DIII (an immunoglobulin-like domain
connected to DI and DII by a ﬂexible linker) (Zheng et al., 2011).
The E2 protein, a type I transmembrane glycoprotein, also comprises
three domains: N-terminal domain A, middle domain B, and C-
terminal domain C (Li et al., 2010). Both E1 and E2 are responsible for
virus entry into host cells. While the E2 glycoprotein interacts with a
cellular receptor, resulting in the virus internalization, the E1
glycoprotein mediates virus fusion to host cell under low pH
conditions (Fields and Kielian, 2013). After the fusion of the viral
envelope with the endosomal membrane, the viral genomic RNA is
released into the cytoplasm and starts replication (Jose et al., 2009;
Solignat et al., 2009). The E proteins accumulate on the surface of
host cells, thereby allowing the budding of viral progeny (Garoff
et al., 2004; Soonsawad et al., 2010; Solignat et al., 2009).
Injecting mice with serum from chikungunya patients in
the convalescent phase of the disease protects them from lethal
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infection, suggesting that monoclonal antibodies (MAbs) are a
potential therapeutic treatment (Couderc et al., 2009). Indeed,
human MAbs against CHIKV show high neutralizing activity and
can be used to both prevent and treat CHIKV infection in mice
(Warter et al., 2011, Fric et al., 2013, Pal et al., 2013). Neutralizing
antibodies mostly prevent virus infection by interfering with the
virus attachment, fusion, or uncoating processes (Reading and
Dimmock, 2007).
Here, we generated a panel of mouse MAbs speciﬁc for CHIKV.
One of the MAbs (CK47, speciﬁc for the CHIKV E1 protein)
effectively reduced the size of viral plaques, although the number
of plaques remained constant. Treating CHIKV-infected cells with
the MAb led to a signiﬁcant reduction in progeny virus secreted
into the extracellular supernatant; however, the MAb had no effect
on intracellular virus replication. Moreover, the result of immuno-
ﬂuorescence assay with confocal microscope showed that treat-
ment with CK47 causes to accumulate virus along the border of
cells during the process of maturation, suggesting that this MAb
inhibits virus release. Taken together, these data provide impor-
tant information that will further our understanding of the CHIKV
life cycle. In addition, CK47 may have potential for future devel-
opment as a therapeutic agent.
Results
Generation and characterization of neutralizing MAbs
IFA screening identiﬁed eight hybridoma clones, CK47, CK20,
CK33, CK41, CK117, CK56, CK116, and CK119, as secreting anti-
CHIKV antibodies (data not shown). All MAbs were of the IgG
isotype: CK56, CK116, and CK119 were IgG1, CK20, CK33, CK47, and
CK117 were IgG2a, and CK41 was IgG2b (Table 1). We next
performed the PRNT to establish whether these MAbs suppressed
plaque formation. Only one MAb, CK47, efﬁciently suppressed
plaque formation (Table 1). CK47 reacted with other CHIKV strains,
ECSA genotypes, SL11131 and S27 and Asian genotype, SBY59/10
but not another alphavirus, Sindbis virus (data not shown).
We next examined the reactivity of CK47 by performing Western
blotting with CHIKV-infected cell lysates. CK47 speciﬁcally recog-
nized a protein with a molecular weight of 50 kDa, which corre-
sponded to the CHIKV E protein (Fig. 1A). Next, CHIKV-infected cells
were incubated with CK47 under permeabilizing or non-
permeabilizing conditions, and the cells were examined by the IFA.
Positive IFA signals were observed under both conditions. This is
consistent with recognition of a viral antigen on the surface of the
cells (Fig. 1B). In addition, the result of sandwich ELISA using cell-free
CHIKV supernatant as an antigen indicated that CK47 binds to CHIKV
particle directly (Fig. 1C). To identify the proteins recognized by CK47,
we transfected 293 T cells with a plasmid expressing recombinant
CHIKV E1 or E2 proteins. CK47 recognized the recombinant CHIKV E1
protein, but not the recombinant E2 protein, in transfected cells
(Fig. 1D). These data indicated that the MAb CK47 interacts with the
E1 protein on the surface of infected cells.
Next, we identiﬁed the epitope on the CHIKV E1 protein
recognized by CK47. To do this, we sequentially propagated CHIKV
in the presence of CK47 or non-neutralizing antibody (as a
control). After eight rounds of passage, CK47 lost its ability to
inhibit plaque formation (Fig. 2A). Amino acid sequencing revealed
that the E1 protein of virus propagated in the presence of CK47
harbored a mutation in E1 (E350G), which was not present in the
virus propagated with a control antibody (Fig. 2B). No mutation
was identiﬁed in the CHIKV E2 protein. Taken together, we can
conclude that CK47 speciﬁcally binds to the CHIKV E1 protein and
that the amino acid residue at position 350 may be important for
epitope recognition.
Small plaques are formed in the presence of CK47
When infected cells were cultured in the presence of CK47,
small plaques were formed. This phenomenon was frequently
observed for the CHIKV isolate from Thailand and for the
SL11131 strain isolated from a returnee to Japan from Sri Lanka
(Lim et al., 2009). Repeated experiments (all with the same result)
led us to conclude that although CK47 reduced plaque size,
it had no effect on plaque number (Fig. 3A). Larger plaques were
observed in the PRNT assay when CK47 was used at higher
dilutions (Fig. 3B). These results suggest that CK47 does not inhibit
CHIKV entry into host cells, but rather inhibits a step that occurs
later in the viral life cycle.
CK47 inhibits the release of CHIKV particles
To examine the mechanism underlying the formation of small
plaques in the PRNT formation in the presence of CK47, cells were
treated with CK47, a non-inhibiting antibody (CK117), an anti-
Flavivirus MAb (4G2), or medium both before and after infection
with CHIKV (Fig. 4A). Virus entry in each test was conﬁrmed by
IFA. The plaque sizes are shown in Fig. 4B. In the standard PRNT,
treatment with CK47 during the virus adsorption and post-entry
steps resulted in the formation of small plaques. However, treat-
ment with CK47 at the pre-entry or adsorption steps resulted in
the formation of plaques with a similar size to those of cells
treated with the controls (CK117, anti-Flavivirus, or medium
alone). Thus, we concluded that CK47 inhibits virus-induced
plaque formation at the post-entry stage.
To determine whether CK47 affected virus production, CHIKV-
infected cells were treated with MAbs (Fig. 5A, upper panel) and
the viral titer in the supernatant was measured at 24 h post-
infection (Fig. 5A, lower panel). The results showed that treating
infected cells with CK47 at the post-entry stage led to marked
inhibition of virus production. To investigate the mechanisms by
which CK47 reduced the releasing efﬁciency, CHIKV-infected cells
were cultured with or without CK47 and observed by confocal
microscope (Fig. 5B). In the absence or CK117 MAb, ﬂuorescent dye
recognized virus were distributed in cytoplasma evenly. By con-
trast, when infected cells were cultured with CK47, the CHIKV
were accumulated along the border of cells. To further examine
the effects of CK47 on CHIKV replication, we compared intracel-
lular and extracellular viral RNA copy numbers at 3, 6, 9, and 12 h
post-infection (Fig. 5C). The results showed that viral RNA copy
numbers in culture supernatants from infected cells treated with
CK47 were signiﬁcantly lower than those in the supernatants from
controls, i.e., cells treated with CK117 or medium alone (Fig. 5C,
left panel). However, there was no signiﬁcant difference between
the viral RNA copies numbers in infected cells treated with CK47
or controls cells (Fig. 5C, right panel). Consequently, CK47 inhib-
ited virus release without affecting virus replication.
Table 1
Characteristics of anti-chikingunya virus monoclonal antibodies.
MAb IFA Western blot IgG isotype Virus inhibition
CK47 þ E. IgG2a þ
CK20 þ E. IgG2a 
CK33 þ E. IgG2a 
CK41 þ E. IgG2b 
CK117 þ E. IgG2a 
CK56 þ  IgG1 
CK116 þ  IgG1 
CK119 þ  IgG1 
MAb: monoclonal antibody, IFA: Indirect immunoﬂuorescence assay.
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Discussion
The MAb CK47, which was obtained from a mouse immunized
with CHIKV-infected murine cells, showed neutralizing activity
against CHIKV. This MAb recognized the viral E1 protein and
inhibited virus release from infected cells. Generally, neutralizing
antibodies inhibit virus production by blocking virus attachment
to host receptors or by interfering with the virus entry/fusion
process (Lum et al., 2013). By contrast, the MAb CK47 inhibited the
virus budding and release processes.
Previous studies reported MAbs that inhibit the release of
Marburg virus, Sendai virus, and Rubella virus, for which the
maturation process commonly occurs at the surface of the infected
cell (Kajihara et al., 2012; Orvell and Kristensson, 1985; Dowdle
et al., 1974). Another study reported an anti-neuraminidase anti-
body that binds to viral proteins on the infected cell surface
and inhibits the release of inﬂuenza virions (Dowdle et al., 1974).
In addition, an antibody that recognizes the hemagglutinin–
neuraminidase proteins expressed by Sendai virus that inhibits
virus shedding, as evidenced by the accumulation of virus particles
at the plasma membrane of infected cells (Orvell and Kristensson,
1985). Similar to these enveloped viruses, CHIKV expresses E
proteins, and virus maturation occurs at the plasma membrane
of infected cells. Thus, it is reasonable that the CHIKV E1 protein is
a target for CK47. Recently, Pal et al. (2013) reported that CHIKV
MAbs show antivirus activity at the post-attachment step. It is
unclear how the CK47 MAb inhibits progeny virus production at
the post-attachment step. It is possible that binding of speciﬁc
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Fig. 1. Speciﬁcity of the CK47 MAb for CHIKV. Speciﬁc binding of the CK47 to viral proteins and virus-infected cells was examined by (A) Western blot analysis and by (B) the
IFA under permeabilizing and non-permeabilizing conditions, respectively. (C) The binding of CK47 to cell-free CHIKV was determined by sandwich ELISA. The 96-well
microplates were coated with CK47, irrelevant antibody (Control MAb: anti-Flavivirus 4G2), and PBS control (No MAb). Then, plates were incubated with cell-free CHIKV
supernatant (Gray Bar) or PBS negative control (White bar). Each sample was performed in triplicate wells. Error bars indicate the standard deviation. p-Values were
calculated using Student's t-test (SPSS). nnpo0.01. (D) 293T cells expressing the CHIKV E1 or E2 proteins were probed with CK47 to identify the target protein(s).
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antibodies to viral surface proteins negatively modulates the
distribution and release of virus progeny, as in the case of human
herpesvirus (Shiraki et al., 2011). Thus, we speculate that CK47
may interfere with the virus E1 protein, making it difﬁcult for the
virus to spread to adjacent cells, and leading to a reduction in
plaque size and overall virus production. This is strongly supported
by the ﬁnding that CK47 binds to the CHIKV E1 protein and causes
the accumulation of CHIKV on the infected cell surface. Interest-
ingly, binding of CK47 markedly impeded virus release, without
affecting intracellular virus replication. This suggests that MAb
binding may interfere with the conformation of the viral E protein,
thereby inhibiting the release of progeny virus into the culture
ﬂuid (Fig. 1A and D, lower panel).
Little is known about the function of the E1 protein during the
virus release process. During CHIKV maturation, precursor E2 and
E1 (p62E1) proteins are formed in the endoplasmic reticulum
(Sjöberg and Garoff, 2003). The complex is transported to the
plasma membrane, where it is cleaved into a mature E1–E2
complex, which then forms trimeric E1–E2 heterodimers at the
plasma membrane (Li et al., 2010). E proteins participate in this
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Fig. 2. Plaque morphology and amino acid sequence alignment of the E1 protein of
CHIKV propagated in the presence of the CK47 MAb. (A) Plaque formation by CHIKV
after eight rounds of passage in the presence (escape mutant; EM) or absence
(wild-type; WT) of CK47. (B) Alignment of the amino acid sequences for the E1
protein from CHIKV strain SL11131, Thai-isolate CHIKV WT, and EM. The point
mutation in the Thai-CHIKV escape mutant (E350G) is indicated by an asterisk.
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Fig. 3. Plaque size reduction in the presence of CK47 MAb. (A) Vero cells were
infected with CHIKV, Thai-CHIKV, or SL11131 in the presence or absence of CK47.
Plaque formation was visualized by methylene blue staining. High magniﬁcation
images of plaques formed by Thai-CHIKV are shown in the right panels.
(B) Inhibitory activity of CK47. Representative images of plaque formation by
Thai-CHIKV (25 PFU) in the absence or presence of CK47 at different concentrations
(250, 62.5, 15.6, 3.1, and 0.8 mg/ml). CK117 was used as control MAb.
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Fig. 4. Plaque size before and after treatment with CK47 MAb. The inhibitory effect
of CK47 was examined in a plaque inhibition assay. (A) 1) Standard protocol: MAb
(CK47, CK117, or anti-Dengue) or medium alone was incubated with 25 PFU of
CHIKV and then used to inoculate Vero cells. The medium was then overlaid
without removing the MAb. 2) Pre-entry inhibition test: Vero cells were pre-
treated with MAbs (CK47, CK117, or anti-Flavivirus) or medium alone for 1 h at
37 1C. The MAb was then removed prior to CHIKV inoculation. 3) Absorption
process inhibition test: MAbs (CK47, CK117, or anti-Flavivirus) or medium alone was
mixed with CHIKV and used to inoculate Vero cells. The inoculum containing the
virus-antibody complex was then removed prior to overlay with CMC medium. 4)
Post-entry inhibition test: Vero cells were inoculated with CHIKV for 1.5 h at 37 1C.
The cells were then washed and overlaid with CMC medium containing MAbs
(CK47, CK117, or anti-Flavivirus) or medium alone. Right panels; The IFA image of
each test. (B) Mean CHIKV plaque diameters were measured under each treatment
condition. Error bars indicate the standard deviation. p-Values were calculated
using one-way ANOVA (SPSS). nnpo0.01.
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process. Kail et al. (1991) found that the cytoplasmic domain of
alphavirus E2 comprises short amino acid residues that interact
with the nucleocapsid and are required for virus assembly.
Mutagenesis studies show that the alphavirus transmembrane
region is involved in E1–E2 heterodimer formation, which largely
affects virus budding (Sjöberg and Garoff, 2003). This indicates
that a properly organized heterodimer is critical for virus shedding
and that blocking the E protein negatively affects virus release.
Here, we showed that the MAb CK47 recognizes a short amino acid
sequence around amino acid E350, which is located within the DIII
region of the E1 protein. Therefore, this domain within CHIKV E1
may be a potential target for inhibiting virus production.
Conclusions
The present study showed that a murine MAb, CK47, inhibits
the release of CHIKV from infected cells. This antibody may have
potential for development as a therapeutic antibody. Passive
transfer of anti-inﬂuenza virus A M2 antibodies inhibits plaque
enlargement and virus replication in mice (Treanor et al., 1990);
therefore, further studies should examine whether CK47 has
similar effects. Here, we showed that CK47 inhibited plaque
formation and virus release from infected cells. Thus, this antibody
may be a potential therapeutic agent. Furthermore, detailed
analysis of the CK47 MAb may enable further understanding of
the mechanism(s) underlying antibody-mediated virus inhibition
and the CHIKV release process.
Materials and methods
Viruses and cells
CHIKV was isolated from Vero cells infected with plasma
obtained from a patient during the 2010 epidemic in Thailand
(Puiprom et al., 2013). The genotype was conﬁrmed by sequence
analysis, and phylogenetic analysis revealed that the isolate
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Fig. 5. Effects of CK47 MAb on CHIKV ﬁtness and gene replication. (A) Cells were infected with CHIKV at a MOI of 0.1 and then treated with MAb. The viral titer in the culture
supernatant was measured at 24 h post-infection. (B) Immunoﬂuorescence images of CHIKV-infected cells (MOI; 1) in the presence of CK47 were observed with confocal
microscope at 8 h post-infection. Infected cells were incubated with anti-CHIKV mouse polyclonal antibody and stained with Alexa Fluor 488. (C) Cells were infected with
CHIKV at a MOI of 3 and then treated with MAb. Supernatant (left panel) and cell (right panel) fractions from each culture were harvested at 3, 6, 9, and 12 h post-infection.
RNA was extracted from these fractions, and the viral copy number was determined by real-time RT-PCR. Error bars indicate the standard deviation for three independent
experiments. p-Values were calculated using Student's t-test (SPSS). npo0.05 and nnpo0.01.
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clustered within the ECSA lineage. A CHIKV SL11131 strain (ECSA
genotype) isolated from a returnee from Sri Lanka to Japan was
kindly provided by Dr. Chang-Kweng Lim (National Institute of
Infectious Diseases, Japan; Lim et al., 2009).
BALB/c-derived B7 cells (Kanai et al., 2010), 293 T cells, and
Vero cells were grown in Eagle's minimum essential medium
(HyClone Laboratories, UT) supplemented with 10% fetal bovine
serum (FBS; GIBCO, Carlsbad, CA). Mouse myeloma PAI cells were
cultured in RPMI 1640 (HyClone) containing 10% FBS. All cell lines
were cultured at 37 1C (95% air/5% CO2).
CHIKV-speciﬁc mouse MAbs
Mouse MAbs were generated as described previously (Masrinoul
et al., 2011). Brieﬂy, B7 cells were infected with CHIKV and incubated
until extensive cytopathic effects were observed. Infected cells were
inactivated with phosphate-buffered saline (PBS) containing 4%
formaldehyde overnight at 4 1C, harvested, washed three times with
PBS, and stored at 80 1C prior to injection. Five-week-old female
BALB/c mice (National Laboratory Animal Center, Mahidol University,
Bangkok, Thailand) were immunized intraperitoneally with inacti-
vated CHIKV-infected B7 cells (2.5106 infected cells/mouse) in
complete Freund's adjuvant (Sigma Aldrich, Saint Louis, MO). The
mice were boosted three times every 3 weeks with CHIKV-infected
cells without adjuvant. Three days after the ﬁnal boost-immuniza-
tion, spleens were removed and spleen cells were obtained and fused
with mouse myeloma PAI cells using polyethylene glycol ♯1500
(Roche diagnostics, Mannheim, Germany). Fused cells were cultured
in RPMI 1640 supplemented with 15% FBS, hypoxanthine–aminop-
terin–thymidine (GIBCO, Grand Island, NY), and 3% BM-Condimed H1
supplement (Roche diagnostics). The antibodies secreted by the
hybridomas were screened in an indirect immunoﬂuorescence assay
(IFA) using CHIKV-infected Vero cells. Hybridomas secreting anti-
bodies that generated a positive IFA signal were cloned twice by
limiting dilution, and the isotype of the antibodies was determined
by immunochromatography using the IsoQuick™ kit (Sigma).
To generate ascitic ﬂuid, pristane-primed mice were intraper-
itoneally injected with the hybridomas and the ascitic ﬂuid was
puriﬁed on protein G Sepharose™ 4 Fast Flow (GE Healthcare,
Uppsala, Sweden) according to the manufacturer's protocol. The
antibody concentrations were measured using the Bradford Pro-
tein Assay (BIO-RAD Laboratories, Hercules, CA).
Expression of CHIKV E1 and E2 proteins
The CHIKV 6k-E1 and E2-6k genes were PCR-ampliﬁed from a
molecular clone of CHIKV Ross strain. An in-frame translation
codon was introduced at the 50 end of each fragment and a
termination codon was introduced into each E2-6k fragment using
gene-speciﬁc primers. The ampliﬁed PCR products were then
cloned into the mammalian expression vector pcDNA3.1Zero
(Invitrogen). 293 T cells were transfected with the pcDNA3.1zero
plasmid containing the CHIKV 6k-E1 and E2-6k sequences
using the FuGENE HD Transfection Reagent (Roche) according to
the manufacturer0s instructions. Expression of the fragments
was conﬁrmed by IFA. The reactivity of the anti-CHIKV MAbs
and anti-CHIKV rabbit serum (positive control) against each of the
expressed E proteins was examined by the IFA.
Plaque reduction neutralization test (PRNT)
The PRNT was performed using Vero cells cultured in 12-well
microplates. Antibodies were serially diluted to obtain ﬁnal con-
centrations of 250, 62.5, 15.6, 3.1, and 0.8 mg/ml before mixing with
25 PFU/ml of CHIKV. The mixtures were then incubated for 1 h at
37 1C. Monolayers of Vero cells were inoculated with 50 ml of the
CHIKV–MAb complexes and incubated for 90 min. To examine the
inhibitory activity of the MAbs, Vero cells were incubated with
MAb for 1 h prior to viral infection or after the absorption period.
The cells were then overlaid with medium containing 2% carboxyl-
methyl cellulose (CMC) and 10% FBS, and incubated for a further
3 days at 37 1C. Finally, the cells were ﬁxed with PBS containing 4%
formaldehyde for 30 min before staining with methylene blue. The
size of individual plaques was measured and the plaque number
was counted.
IFA assay
CHIKV-infected and mock-infected Vero cells were cultured for
24 h and then ﬁxed with PBS containing 4% formaldehyde for
20 min. The ﬁxed cells were treated either with or without 1%
Triton X-100 for 5 min, and then stringently washed with PBS.
Finally, the cells were incubated with hybridoma culture super-
natant at 37 1C for 30 min, followed by goat anti-mouse IgG
conjugated to Alexa Flour 488 (1:500; Invitrogen, Carlsbad, CA)
for 30 min at 37 1C. After removing excess unbound antibody, cells
were observed under a ﬂuorescence microscope (IX71, Olympus
Tokyo, Tokyo, Japan) and confocal microscope (FV1000, Olympus
Tokyo, Tokyo, Japan).
Western blotting
The reactivity of MAbs with viral proteins was analyzed by
Western blotting under reducing conditions, as described previously
(Noda et al., 2012). Brieﬂy, CHIKV-infected Vero cell lysates were
mixed with SDS-PAGE sample buffer containing β-mercaptoethanol
and heated at 100 1C for 5 min. After electrophoresis, the separated
proteins were transferred to polyvinylidene ﬂuoride membranes (GE
Healthcare, Buckinghamshire, UK). The membranes were incubated
with MAbs overnight at 4 1C and then reacted with anti-mouse IgG
conjugated with horseradish peroxidase (HRP) (KPL, Gaithersburg,
MD) for 1 h. Bound antibodies were detected using the ECL Western
blotting detection reagent (GE Healthcare, Buckinghamshire, UK).
Enzyme-linked immunosorbent assay (ELISA)
The binding of anti-CHIKV MAb to cell-free CHIKV was deter-
mined by sandwich ELISA. Ninety six-well plates (Bio-Rad) were
coated with anti-CHIKV MAb, irrelevant antibody (anti-Flavivirus
4G2), and PBS control in 0.1 M bicarbonate buffer (pH 9.6) at 4 1C
overnight. Wells were blocked with 5% skim milk in PBS–0.05%
Tween 20 for 2 h at room temperature. After washing with PBS–
0.05% Tween 20, the plates were added with CHIKV supernatant or
PBS control for 90 min at room temperature. After stringently
washed, the anti-CHIKV rabbit serum at a dilution of 1:500
was added and incubated for 1 h at room temperature. Then,
plates were washed and incubated with goat anti-rabbit conju-
gated with HRP (R&D systems) at a dilution of 1:2000 for 1 h at
room temperature. After washing, tetramethylbenzidine substrate
(KPL) was added and incubated for 5 min. The reaction was
stopped by adding 0.1 M sulfuric acid and measured at absorbance
450 nm. Each sample was tested in triplicate wells.
Real-time reverse transcriptase polymerase chain reaction (RT-PCR)
Vero cells were infected with CHIKV at a multiplicity of
infection (MOI) of 3 for 90 min prior to the addition of 100 ml
of anti-CHIKV or control antibody (250 mg/ml). The infected
cells and culture supernatant were collected at 3, 6, 9, and 12 h
post-infection. RNA was extracted from the culture supernatant
using a QIAamp Viral RNA Mini kit (QIAGEN, Hilden, Germany) and
from infected cells using Trizol reagent (Invitrogen), according to
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the manufacturer's instructions. The QuantiTect SYBR Green
RT-PCR kit (QIAGEN) was used for quantitative real-time RT-PCR
using the following primers: CHIKV-E1-F (CTCATACCGCATCCG-
CATCAG) and CHIKV-E1-R (ACATTGGCCCCACAATGATATTG).
GAPDH mRNA was used as an internal control (Okabayashi et al.,
2006). Ampliﬁcation was performed under the following condi-
tions: reverse transcription at 50 1C for 30 min and inactivation of
the enzyme at 95 1C for 15 min, followed by 44 cycles of denatura-
tion at 95 1C for 20 s, annealing at 55 1C for 30 s, extension at 72 1C
for 30 s, and a ﬁnal extension step at 65 1C for 5 s (CFX96 real-time
system, C1000 thermal cycler; Bio-Rad, Tokyo, Japan). Quantiﬁca-
tion of viral RNA was performed using cycle threshold values and
the ΔΔCt method.
Selection of an escape mutant by serial passage of CHIKV with an
anti-CHIKV MAb
Vero cells were infected with CHIKV (200 PFU) for 90 min at
37 1C, followed by treatment with CK47 (250 mg/ml). A non-
neutralizing antibody (CK117) was used as a negative control.
Viruses were harvested and continually passaged with MAb as
described above until a loss of inhibition was observed in the
plaque assay. The supernatant was then collected, and the nucleo-
tide and amino acid sequences of the CHIKV E1 and E2 regions
were analyzed.
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